Masataka Oitate

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara et al. · Clinical Cancer Research · 2016 · 1K citations · Full text

Bystander killing effect of <scp>DS</scp>‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

Yusuke Ogitani, Katsunobu Hagihara, Masataka Oitate et al. · Cancer Science · 2016 · 660 citations · Full text

Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys

Yoko Nagai, Masataka Oitate, Hideyuki Shiozawa et al. · Xenobiotica · 2018 · 94 citations

Drug Targeting, Preclinical Drug Evaluation, Cynomolgus Monkeys +13

Prediction of Human Pharmacokinetics of Therapeutic Monoclonal Antibodies from Simple Allometry of Monkey Data

Masataka Oitate, Noriko Masubuchi, Takashi Ito et al. · Drug Metabolism and Pharmacokinetics · 2011 · 78 citations

CS-8958, a Prodrug of the Novel Neuraminidase Inhibitor R-125489, Demonstrates a Favorable Long-Retention Profile in the Mouse Respiratory Tract

Kumiko Koyama, Makoto Takahashi, Masataka Oitate et al. · Antimicrobial Agents and Chemotherapy · 2009 · 75 citations · Full text

Medicine, Immunology, Radioactivity Concentrations +12